Apellis Pharmaceuticals Aktie (A2JAAW

Chart der Apellis Pharmaceuticals Aktie

Charttool öffnen

Aktuelle Nachrichten zu Apellis Pharmaceuticals

Weitere Nachrichten

Das berichten andere über Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +139.30% and +33.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues...

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some...

Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6...

Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio

Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio ?of ?rare-disease medicines.